Skip to content

Crinetics Pharmaceuticals, Inc.

CRNX

CIK 0001658247

← back to feed
Revenue (TTM)
$12.27M
+640.7% YoY Q1 Apr 2026
Net Income (TTM)
−$470.35M
−55.9% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$4.88
−34.1% YoY Q1 Apr 2026
Gross Margin
91.2%
Q1 Apr 2026
Operating Margin
-4,266.7%
Q1 Apr 2026
Net Margin
-3,833.6%
Q1 Apr 2026
Free Cash Flow (TTM)
−$310.14M
Q1 Apr 2026
Cash
$114.34M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
105.44M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings